
LBRX Stock Forecast & Price Target
LBRX Analyst Ratings
Bulls say
LB Pharmaceuticals is supported by a de-risked lead asset in LB-102, which has already shown statistically significant Phase 2 schizophrenia efficacy across all three doses, including placebo-adjusted PANSS improvements of 5.0, 4.7, and 6.8 points, alongside dose-dependent cognitive gains and a favorable tolerability profile with low EPS and minimal sedation. The fundamental bull case also rests on a differentiated, re-engineered amisulpride platform that enables once-daily dosing at far lower exposure than the ex-U.S. drug, while preserving a bimodal mechanism that can extend into bipolar depression and adjunctive MDD. With pro forma cash of about $478M funding operations beyond Q2 2029 and catalysts spanning NOVA-2 in 1H 2027, ILLUMINATE-1 in Q1 2028, and adjunctive MDD in 1H 2029, the company has both scientific and financial runway.
Bears say
LB Pharmaceuticals is exposed to substantial clinical and regulatory risk because its outlook depends on LB-102 succeeding in late-stage development while the company itself flags NOVA-2 primary miss risk, unexpected safety and tolerability signals, and possible delays in schizophrenia and bipolar depression programs. The bearish case is reinforced by competitive pressure and weakening category evidence, including emraclidine’s failed registrational Phase 2 dose, Cobenfy’s largest Phase 3 missing its prespecified PANSS-negative endpoint at week 5, and the broader observation that efficacy can diminish in larger Phase 3 studies. Finances also remain a concern, as the company faces financing risk until cash flow positive, while step-therapy positioning, other R&D setbacks, and regulatory uncertainty could limit commercial optionality.
This aggregate rating is based on analysts' research of LB Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.
LBRX Analyst Forecast & Price Prediction
Start investing in LBRX
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About LB Pharmaceuticals Inc (LBRX) Forecast
LBRX Analyst Forecast & Price Prediction
Start investing in LBRX
Order type
Buy in
Order amount
Est. shares
0 shares